Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
Go back to Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026| (NASDAQ: RVMD) | Delayed: 192.76 +1.81 (0.95%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $190.95 | 52 Week High | $ | |||
| Open | $192.60 | 52 Week Low | $ | |||
| Day High | $194.93 | P/E | N/A | |||
| Day Low | $190.57 | EPS | $ | |||
| Volume | 1,888,882 | |||||
